Canagliflozin: Cui Bono?

Circulation. 2018 Jan 23;137(4):335-337. doi: 10.1161/CIRCULATIONAHA.117.032198. Epub 2017 Nov 13.

Authors

Matthew A Cavender^{1

2}, Mikhail Kosiborod^{3

4}

Affiliations

¹ Department of Medicine, University of North Carolina, Chapel Hill (M.A.C.) [email protected].
² Department of Medicine, Baim Institute for Clinical Research, Boston, MA (M.A.C.).
³ Department of Medicine, St Luke's Mid America Heart Institute, Kansas City, MO (M.K.).
⁴ Department of Medicine, University of Missouri-Kansas City (M.K.).

PMID: 29133603
DOI: 10.1161/CIRCULATIONAHA.117.032198

No abstract available

Keywords: Editorials; diabetes mellitus, type 2; heart failure; primary prevention; secondary prevention.

Publication types

Editorial
Comment

MeSH terms

Canagliflozin*
Hypoglycemic Agents
Secondary Prevention
Sodium-Glucose Transporter 2 Inhibitors*

Substances

Hypoglycemic Agents
Sodium-Glucose Transporter 2 Inhibitors
Canagliflozin